◆ 会议时间：2026年1月8-10日
◆ 会议地点：美国 旧金山(San Francisco)

◆ 会议简介：

2026年ASCO胃肠道肿瘤研讨会(ASCO-GI2025)将于2026年1月8-10日在美国加利福尼亚州旧金山举行。ASCO胃肠道(GI)癌症研讨会是一个肿瘤学专题活动，旨在为胃肠道癌症护理和研究组织的成员提供科学和教育内容；为期三天的会议包含了食道、胃、胰腺、小肠和肝胆道、结肠、直肠和肛门等部位癌症的最新科学。会议由美国临床肿瘤学会(ASCO)、美国胃肠病学会(AGA)、美国放射肿瘤学会(ASTRO)、美国外科肿瘤学会(SSO)联合举办。未经许可禁止复制转载摘录本站任何内容-领域国际医学会议网(lingyuint.com)。

美国临床肿瘤学会(ASCO)成立于1964年，是世界上最大、最具影响力的肿瘤专业学术组织，致力于癌症的预防、治疗及改善对患者的护理，ASCO是唯一涵盖所有肿瘤亚专科的组织。ASCO在全球150多个国家和地区拥有超过45000名成员，其中国际会员约占协会会员总数的三分之一，会员包括肿瘤学领域宣及其亚专科的临床肿瘤科医师、参与认可的肿瘤学训练计划的医师和医疗专家、肿瘤科护士以及肿瘤科执业医师等等。

2026 ASCO Gastrointestinal Cancers Symposium (GI2026)

Date:
January 8-10, 2026

Venue:
Moscone West，San Francisco, California, United States

Co-sponsored by：
American Society of Clinical Oncology (ASCO)
American Gastroenterological Association (AGA)
American Society for Radiation Oncology (ASTRO)
Society of Surgical Oncology (SSO)

The Gastrointestinal (GI) Cancers Symposium is a specialized oncology event designed to provide scientific and educational content for members of the GI cancer care and research community. This three-day meeting encompasses the latest science in cancers of the esophagus and stomach; the pancreas, small bowel, and hepatobiliary tract; and the colon, rectum, and anus. 

摘要征文投稿：

Abstract Submission Deadline: September 9, 2025, at 11:59 PM (EST)
Late-Breaking Abstract Submission Deadline: October 9, 2025, at 12:00 PM (EST)
Abstract Change/Withdrawal Deadline: November 14, 2025, at 12:00 PM (EST)

点此提交摘要>>>

点此查看摘要指南>>>

Submission Fee: An $80 (USD) nonrefundable submission fee will be charged per abstract submitted.

Submission Requirements

• ASCO Account: To submit an abstract, you will need to log in with an ASCO.org account. If you are not an ASCO member, you can create a guest account. To improve account security, ASCO has implemented a new login process. If you are a first-time user of this process, please follow the on-screen prompts to update your account during login. For troubleshooting, refer to the 'Need Help Logging In' section of the ASCO Customer Account Assistance page. The person submitting the abstract is not required to be an author on the abstract and will be able to select the first/presenting author on the designated step. However, the first author will need to accept/agree to all ASCO policies and will be held responsible for any violation of the policies.
• Identification of Original Research: Indicate whether your abstract reports on original research. Original research means a systematic investigation designed for the purpose of expanding knowledge or understanding, including the analysis of data.
• Identification of Clinical Trials: Indicate whether your research is a clinical trial. A clinical trial is: a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes (National Institutes of Health [NIH] Office of Extramural Research.)
  • Though clinical trial registration is not required for abstract submission, publication, or presentation, certain clinical trials are required to be registered by law and/or prior to journal publication. If a clinical trial is already registered, the first author will be asked to provide the name of the registry and the trial registration number during the abstract submission process. The clinical trial number will be included as part of the published abstract.
• Funding Source: Indicate whether the abstract was funded by the NIH, a pharmaceutical or biotechnology company, a tobacco company, a foundation, or another source 
• Abstract Title: The title should objectively describe the study. Do not refer to study results or conclusions. ASCO reserves the right to edit conclusive titles.
• Use of Proprietary Drug Names: Do not use proprietary drug names in your abstract body or title; use generic names instead (e.g., "Herceptin" should be written as "trastuzumab"). If the proprietary name is the only one used for the particular drug or product to which you are referring (e.g., HercepTest or CyberKnife), you may use that name; however, do not include a trademark or registration symbol.
• Coauthor(s): Provide the full name, academic degree(s), institution, address, email address, and disclosure information for each author. You may list up to 20 individual authors for each abstract.
• Disclosure Declaration: ASCO’s policy promotes balance, independence, objectivity, and scientific rigor in all of its activities through the disclosure of financial interests and other relationships, and management of potential conflicts. The financial interests or relationships requiring disclosure are outlined in ASCO’s Policy For Relationships With Companies (Journal of Clinical Oncology 2017 35:7, 796-798). All authors are expected to disclose all relationships with for-profit health care companies.
  • Author disclosure must be declared at the time of abstract submission. If the first author is employed by a company or holds ownership with a private company (see company definition below), an alternate presenter who does not have a relevant employment or ownership relationship must be named from the list of coauthors if the abstract is selected for presentation in an education session, oral abstract session or rapid oral abstract session.
    • Company: an entity whose business is developing, producing, marketing, selling, re-selling or distributing drugs, devices, services or therapies used to diagnose, treat, monitor, manage and alleviate health conditions
  • The Coauthor Disclosure Form may be used by the first author to obtain disclosure information from co-authors. The first author must enter all disclosure information through the Abstract Submitter.
  • If an author has provided disclosure through the ASCO Disclosure Management System, the information will automatically populate in the submission site. Disclosure information for all authors will be distributed as part of abstract presentation materials.
• Restrictions for Presenting Authors: At least one coauthor on the abstract must be eligible to present under the CMSS Code for Interactions with Companies. If the first author is employed by a company, or holds ownership with a private company as defined by the CMSS Code for Interactions with Companies (see below), an alternate presenter who does not have a relevant employment or ownership relationship must be named, from the list of coauthors. This applies to abstracts presented in an oral abstract session or rapid oral abstract session. These presenters will also be subject to the same disclosure review and management strategies as faculty, per ASCO’s Implementation Plan to Manage Relationships with Companies for CE Activities.
  • Company: “An entity whose business is developing, producing, marketing, selling, re-selling or distributing drugs, devices, services or therapies used to diagnose, treat, monitor, manage and alleviate health conditions.”
• Abstract Body/Table: The body of your abstract should describe the background, methods, results, and conclusions of your research. You may type your abstract directly into the text box, cut and paste from an existing document, or upload a text file of your abstract. Do not exceed 2,600 characters (approximately 300 to 350 words) for the total of your abstract title, body including section titles, and table. The character count does not include spaces or author names or institutions. One data table is permitted per abstract. The composition process does not enable shading or the merging of cells with centered text. Limit your table to no more than 10 rows and eliminate the need for shading or merged cells with centered text. Illustrations and figures are not permitted.
• Submission Track: Select the most appropriate track and subcategory for the abstract (see Submission Tracks and Subcategories). The ASCO GI Symposium Program Committee has the authority to recategorize an abstract.
• Submission Fee: An $80 (USD) nonrefundable submission fee will be charged per abstract submitted. Payment is due at the time of submission. Credit cards are the only accepted form of payment. Checks, wire transfers, and purchase orders will not be accepted.
  • Please note: The abstract submission fee does not include registration for the GI Symposium.
  • Payment waivers: ASCO is pleased to offer payment waivers to first authors residing in low-income countries and lower-middle-income countries (LMICs), as defined by the World Bank. Authors may apply for a payment waiver at the time of submission. Please contact us for more details. These countries include: Afghanistan, Angola, Bangladesh, Benin, Bhutan, Bolivia Burkina Faso, Burundi, Cabo Verde, Cambodia, Cameroon, Central African Republic, Chad, Comoros, Democratic Republic of Congo, Republic of the Congo, Côte d'Ivoire, Djibouti, Egypt, Eritrea, Eswatini, Ethiopia, The Gambia, Ghana, Guinea Guinea-Bissau, Haiti, Honduras, India, Jordan, Kenya, Kiribati, Kyrgyz Republic, Democratic People's Republic of Korea, Lao PDR, Lebanon, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Micronesia, Morocco, Mozambique, Myanmar, Nepal, Nicaragua, Niger, Nigeria, Pakistan, Papua New Guinea, Philippines, Rwanda, Samoa, São Tomé and Principe, Senegal, Sierra Leone, Solomon Islands, Somalia, South Sudan, Sri Lanka, Sudan, Syrian Arab Republic, Tajikistan, Tanzania, Timor-Leste, Togo, Tunisia, Uganda, Uzbekistan, Vanuatu, Vietnam, West Bank and Gaza, the Republic of Yemen, Zambia, and Zimbabwe.

◆ 参会对象：医生、医院科室主任/副主任、住院医师、医院管理者、医护人员以及从事该领域研究的科学家、研究人员、医药企业代表等等。